This European Patent was registered throughout the European Union in Germany, France, Spain, Great Britain, and Italy, and the opposition period has passed.
A corresponding U.S. patent is pending in the U.S. Patent and Trademark Office and is moving through the process.
The European patent claims both self-assembled arrays and a method for making self-assembled arrays on electrode arrays with self-assembled antibodies.
This microarray configuration is useful for arraying proteins specifically antibodies. The technology is designed to enable products such as multiplexed immunoassays, monitoring of biowarfare and terrorist agents, and general protein analysis tools.
"CombiMatrix's intellectual property strategy is designed to provide freedom to operate for CombiMatrix products as well as to establish strong barriers to protect the unique aspects and commercial advantages of our electrochemical synthesis and detection technologies," said Dr. Jeff Oster, Senior Vice President, Legal at CombiMatrix.
"In this case, we decided to wait the nine months after publication of the grant to let the opposition period expire before announcing."